THERAtRAME
ActiveSummary
The annual accounts of THERAtRAME for financial year 2025 show a net loss of 79% of total assets and of 273% of the equity at the start of that year. The 2025 annual accounts show equity of €1.8m and a net result of -€2.1m. Equity is shrinking by about 2.7% per year across the filed financial years. Its solvency ranks better than 60% of 240 sector peers (NACE 72, financial year 2025). The company has been active since 2022 and the Belgian Official Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 0.2% (very low).
Group and network
Connections & network
6 connected companiesThis company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Linked via shared directors
Ageless Ophthalmics
Shared corporate director
→
AILOS
Shared corporate director
→
AnimAb
Shared corporate director
→
RheaVita
Shared corporate director
→
Show 2 more companies with a shared director
STICHTING ADMINISTRATIEKANTOOR AXITHRA
Shared corporate director
→
Swave
Shared corporate director
→